Brilanestrant
Brilanestrant
Brilanestrant (pronunciation: bri-lan-es-trant) is a novel, non-steroidal Selective Estrogen Receptor Degrader (SERD) currently under clinical investigation for the treatment of Estrogen Receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic Breast Cancer.
Etymology
The term "Brilanestrant" is a coined name for this specific drug compound. The name does not have a known etymology as it is a unique identifier for this particular SERD.
Usage
Brilanestrant is being studied as a potential treatment for ER-positive, HER2-negative advanced or metastatic breast cancer. It is designed to bind to the estrogen receptor and degrade it, thereby inhibiting the growth of cancer cells.
Related Terms
- Selective Estrogen Receptor Degrader (SERD): A class of drugs that bind to the estrogen receptor and degrade it, thereby inhibiting the growth of cancer cells.
- Estrogen Receptor (ER): A protein found inside cells that binds to the hormone estrogen and is involved in the growth of cells.
- Breast Cancer: A type of cancer that forms in the cells of the breasts.
- Metastatic Breast Cancer: A stage of breast cancer where the disease has spread to other parts of the body.
- Human Epidermal Growth Factor Receptor 2 (HER2): A protein that promotes the growth of cancer cells. In about one of every five breast cancers, the cancer cells have a gene mutation that makes an excess of the HER2 protein.
External links
- Medical encyclopedia article on Brilanestrant
- Wikipedia's article - Brilanestrant
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski